← SynDRA
RITLECITINIB
SynDRA canonical compound SYN0039265 — structure-anchored drug synonym record
| Clinical phase | Phase 2/Phase 3 |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | JAK3 |
|---|
| Mechanism of action | JAK inhibitor |
|---|
All known targets
- JAK3
- BMX
- BTK
- ITK
- TEC
- TXK
- BLK
- ERBB4
- JAK1
Mechanisms of action (all sources)
- JAK3 INHIBITOR
- Tyrosine-protein kinase JAK3 inhibitor
- ITK INHIBITOR
- TEC family kinase inhibitor
- BMX INHIBITOR
- TEC INHIBITOR
- TXK INHIBITOR
- BTK INHIBITOR
- JAK inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- JAK2
- TYK2
- EGFR
- ERBB2
- MAP2K7
Drug classes
- Janus Kinase Inhibitors
- Tyrosine Kinase Inhibitors
ATC classes
- L04A · IMMUNOSUPPRESSANTS
Cross-references
Synonyms
- LITFULO
- Litfulo
- ritlecitinib tosylate
- PF-06651600
- litfulo
- CBRJPFGIXUFMTM-WDEREUQCSA-N
- UNII-2OYE00PC25
- 2OYE00PC25
- PF06651600
- GTPL9559
- SCHEMBL16764638
- BCP24778
- EX-A2613
- ZINC526061581
- example 5 [WO2015083028]
- ACN-040697
- compound 11 [PMID: 28139931]
- HY-100754
- CS-0020243
- PF 06651600
- RefChem:179511
- JAK3 Inhibitor PF-06651600
- MFCD30343868
- ritlecitinibum
- PF-06651600 free base
- MFCD31697544
- RITLECITINIB [INN]
- RITLECITINIB [WHO-DD]
- orb1301838
- SCHEMBL24377696
- SCHEMBL29369472
- CHEBI:229233
- RITLECITINIB (PF-06651600)
- AKOS040758742
- CCG-267324
- EBC-221083
- NCGC00501213-04
- AC-35550
Look up RITLECITINIB in the interactive SynDRA portal →